The UK government is poised to finalise a significant pharmaceuticals agreement with Washington, set to eliminate import tariffs on medicines entering the United States and commit Britain to increased NHS drug spending. The deal, expected to be announced shortly, follows extensive negotiations with the Trump administration and comes amid warnings and investment withdrawals from multinational drug manufacturers frustrated with the UK’s commercial climate.
Industry sources indicate the agreement will involve the UK government reducing the industry rebate rate on branded medicines sold to the NHS and raising the threshold for NHS drug-value assessments. The quality-adjusted life year (QALY) measure, which evaluates the cost of treatments in relation to the healthy years they provide, will see its upper limit increase by approximately 25% from the current £30,000 per year. Additionally, the government has agreed to allocate a larger portion of the NHS budget to medicines, a longstanding demand from global pharmaceutical firms.
The negotiations have been spearheaded by Varun Chandra, the Prime Minister’s chief business adviser, and Lord Vallance, the Science Minister and former GSK executive. The Trump administration has aimed to close the gap between high US drug prices and lower prices in countries like the UK, using tariff threats as leverage for change.
Alongside government discussions, pharmaceutical industry leaders in both London and Washington have been engaged in talks to ease tensions and restore investment confidence. Relations between the sector and the UK government have deteriorated this year, as drug makers have criticised the high cost of the NHS’s Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG). While the scheme aims to curb NHS medicines spending and encourage innovation, industry leaders argue that UK rebate levels have rendered the country uncompetitive.
The situation escalated in September when several pharmaceutical giants halted or cancelled major UK investments. AstraZeneca paused a £200 million expansion of its Cambridge headquarters, Eli Lilly suspended part of its planned London biotech hub, and Merck/MSD withdrew from a £1 billion London R&D centre. Several manufacturers have indicated that UK facilities might close unless pricing reforms are swiftly agreed upon.
The US ambassador cautioned last month that global pharma groups might “vote with their feet” unless the UK took action. AstraZeneca was among the first to negotiate a separate pricing deal directly with the Trump administration. Formal discussions between the Association of the British Pharmaceutical Industry (ABPI) and the Department of Health broke down in August after Health Secretary Wes Streeting issued an ultimatum to accept what he termed a “generous proposal.” Following industry backlash, Vallance informed MPs in September that the UK needed to increase NHS medicines spending, signalling that helped integrate the VPAG dispute into broader tariff negotiations with Washington.
Industry figures suggest the new deal could alleviate tensions, restore investment, and provide a more stable foundation for drug development in the UK, though the long-term impact on NHS budgets remains to be determined.
You must be logged in to post a comment.